Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines—Lessons Learned From the Global Perspective

Alejandro Ramirez Gonzalez, Margaret Farrell, Lisa Menning, Julie Garon, Hans Everts, Lee M. Hampton, Samantha B. Dolan, Stephanie Shendale, Sarah Wanyoike, Chantal Laroche Veira, Gaël Maufrais du Châtelier, Feyrouz Kurji, Jennifer Rubin, Liliane Boualam, Diana Chang Blanc, and Manish Patel

In 2015, the Global Commission for the Certification of Polio Eradication certified the eradication of type 2 wild poliovirus, 1 of 3 wild poliovirus serotypes causing paralytic polio since the beginning of recorded history. This milestone was one of the key criteria prompting the Global Polio Eradication Initiative to begin withdrawal of oral polio vaccines (OPV), beginning with the type 2 component (OPV2), through a globally synchronized initiative in April and May 2016 that called for all OPV using countries and territories to simultaneously switch from use of trivalent OPV (tOPV; containing types 1, 2, and 3 poliovirus) to bivalent OPV (bOPV; containing types 1 and 3 poliovirus), thus withdrawing OPV2. Before the switch, immunization programs globally had been using approximately 2 billion tOPV doses per year to immunize hundreds of millions of children. Thus, the globally synchronized withdrawal of tOPV was an unprecedented achievement in immunization and was part of a crucial strategy for containment of polioviruses. Successful implementation of the switch called for intense global coordination during 2015–2016 on an unprecedented scale among global public health technical agencies and donors, vaccine manufacturers, regulatory agencies, World Health Organization (WHO) and United Nations Children’s Fund (UNICEF) regional offices, and national governments. Priority activities included cessation of tOPV production and shipment, national inventories of tOPV, detailed forecasting of tOPV needs, bOPV licensing, scaling up of bOPV production and procurement, developing national operational switch plans, securing funding, establishing oversight and implementation committees and teams, training logistics and health workers, fostering advocacy and communications, establishing monitoring and validation structures, and implementing waste management strategies. The WHO received confirmation that, by mid May 2016, all 155 countries and territories that had used OPV in 2015 had successfully withdrawn OPV2 by ceasing use of tOPV in their national immunization programs. This article provides an overview of the global efforts and challenges in successfully implementing this unprecedented global initiative, including (1) coordination and tracking of key global planning milestones, (2) guidance facilitating development of country specific plans, (3) challenges for planning and implementing the switch at the global level, and (4) best practices and lessons learned in meeting aggressive switch timelines. Lessons from this monumental public health achievement by countries and partners will likely be drawn upon when bOPV is withdrawn after polio eradication but also could be relevant for other global health initiatives with similarly complex mandates and accelerated timelines.

Keywords: Polio; eradication; poliovirus; endgame; OPV; oral polio vaccine; IPV; inactivated polio vaccine.

Since the World Health Assembly (WHA) resolved to eradicate polio in 1988, polio cases have declined dramatically, from >350,000 cases annually to 37 cases in 2016 [1]. In the past decade, the world has made significant progress toward polio eradication, including the elimination of endemic transmission of polio in all countries worldwide except Afghanistan, Nigeria, and Pakistan. Indeed, as of 23 September 2015, the World Health Organization (WHO) declared that type 2 wild poliovirus had been eradicated, with the last reported case occurring in 1999 [2]. With the eradication of type 2 wild poliovirus, the world is well into the endgame phase of polio eradication, marked by the global introduction of inactivated polio vaccine (IPV) and phased removal of oral polio vaccine, the containment of remaining polioviruses in laboratories and manufacturing facilities, and the transitioning of polio resources to other public health efforts [3, 4]. Although the world is getting closer to eradication, since types 1 and 3 wild polioviruses have not yet been eradicated, use of OPV continues in many countries worldwide. The withdrawal of OPV is taking place in a phased manner, beginning with the removal of the type 2 component of OPV (OPV2), through a global switch from trivalent oral polio vaccine (tOPV), containing live attenuated poliovirus types 1, 2, and...
3, to bivalent oral polio vaccine (bOPV), containing poliovirus types 1 and 3. Ultimately, the world must cease using all OPV after the eradication of polioviruses, to avoid the transmission of vaccine-related polioviruses and ensure that polio is eradicated.

Switching from tOPV to bOPV is not without risks [4–10]. In the postswitch era, the primary risk is the reemergence of outbreaks involving type 2 circulating vaccine-derived polioviruses (cVDPV2s) in the context of declining population immunity to type 2 poliovirus following withdrawal of OPV2. To mitigate risks related to the reemergence of type 2 viruses, the WHO Strategic Advisory Group of Experts on Immunization (SAGE) proposed risk mitigation activities that have been described elsewhere [4, 6, 7, 11–17]. In the long run, cessation of OPV2 use by immunization programs worldwide should eliminate the risk for outbreaks of cVDPV2 infection, but in the short run, a prolonged, staggered OPV2 withdrawal would pose a risk for continuous generation of VDPV2s and potential exportation of these viruses to regions or countries.

Figure 1. Initial messaging on tentative time frame for the globally synchronized switch from trivalent oral polio vaccine (tOPV), August 2014. Abbreviations: cVDPV2, circulating vaccine-derived poliovirus type 2; pcVDPV2, persistent circulating vaccine-derived poliovirus type 2; RI, routine immunization; SAGE WG, Strategic Advisory Group of Experts on Immunization Working Group; SIA, supplementary immunization activities; WHA, World Health Assembly.
Lessons in the Global Switch From tOPV to bOPV

with susceptible children born after cessation of OPV2 use. Global synchronization of OPV2 withdrawal within a limited time frame was considered the best approach to minimizing this risk. Scheduling the synchronized cessation of OPV2 use during months when endemic circulation of polioviruses in tropical countries is at its lowest point further reduced the risk of poliovirus type 2 infection outbreaks. The WHA endorsed these SAGE recommendations in May 2015 [18], and all OPV-using countries agreed to switch from tOPV to bOPV during a 2-week time period, from 17 April to 1 May 2016 [19].

While most countries had previous experience replacing one vaccine with another (ie, the global transition from diphtheria, tetanus, and pertussis vaccines to newer combination vaccines that also contained hepatitis B virus and Haemophilus influenzae type b antigens), replacement was normally accomplished by depleting existing vaccine stocks and then gradually introducing the new vaccine [20, 21]. One case in which every health facility in a country had simultaneously switched from an existing vaccine to a new vaccine on the same day was the 2010 US switch from 7-valent pneumococcal conjugate vaccine (PCV7) to 13-valent pneumococcal conjugate vaccine (PCV13). For this transition, the manufacturer of both vaccines was controlling and monitoring all cold chain stores that kept PCV7 and PCV13, buying back all PCV7 in existence at the time of the switch, and directing its thousands of sales representatives to monitor stock levels at every health facility using pneumococcal conjugate vaccines, to ensure that there were no stock-outs and that all extra PCV7 was returned [22]. Given this context, the task of synchronizing the switch from tOPV to bOPV so that all vaccine stores and health facilities within a country would switch on the same day and that all countries would switch within a 2-week period, without reimbursement for unused tOPV that was disposed of, was unprecedented. The implementation of the switch was further complicated by uncertainty over whether transmission of VDPV2s would be sufficiently controlled to allow the switch to safely go forward [17], as well as by competing priorities from other global health initiatives (eg, introductions of new vaccines) [23], emergencies, conflicts or natural disasters [24, 25], and large outbreaks of diseases (eg, Ebola and Zika) [26] that could hinder its implementation.

GLOBALLY SYNCHRONIZED SWITCH FROM TRIVALENT OPV TO BIVALENT OPV—A MONUMENTAL PUBLIC HEALTH ACHIEVEMENT

The Global Polio Eradication Initiative (GPEI) selected the dates for the globally synchronized switch in consultation with World Health Organization (WHO) and United Nations Children's Fund (UNICEF) regional offices. A 2-week global window was selected, rather than a single fixed date, to provide programmatic flexibility, allowing countries to adjust their processes and to set more-feasible and more-realistic targets. SAGE unanimously endorsed the recommended dates of the global switch window in its meeting during October 2015 [19].

Before the switch, manufacturers reduced and ultimately stopped production of tOPV, resulting in limited availability of tOPV supply leading up to the switch and its unavailability after the switch. Countries were asked to select a date within the 2-week global switch window, after which they would cease all use of tOPV and, within 2 weeks thereafter, validate that tOPV was no longer being administered. After
discussions with WHO regional offices, Indonesia, Rwanda, and Ghana selected switch dates a few days earlier than the global window because of logistical considerations.

All countries were encouraged to begin switch planning during the first half of 2015 and to finalize a budgeted national switch plan by September 2015 [27]. Of the 155 countries and territories using OPV in early 2015, 118 (76%) had met this milestone by September, and 147 had met it by the end of 2015. Of the 155 countries and territories, 98% (including Belarus, Malaysia, Poland, Tokelau, and Tuvalu, which changed to an IPV-only schedule) reported ceasing use of tOPV by 1 May, and 100% reported stopping use of tOPV by 12 May 2016 [28, 29]. By the time of the 69th Meeting of the WHA, on 26 May 2016, independent monitoring of cold chain facilities had begun in all countries and territories participating in the switch; of the 155 countries and territories using OPV in early 2015, 147 (95%) had provided WHO with an official report validating the country to be free of tOPV [36]. Seven remaining countries provided the official report to the WHO by mid-September 2016. Although ongoing surveillance for remaining tOPV is crucial, the globally synchronized cessation of tOPV use was altogether an unprecedented and successful public health achievement.

OVERVIEW OF THE GLOBAL SWITCH GUIDANCE

The global guiding principles for planning the switch focused on maintaining adequate and uninterrupted supply of tOPV up until the time of the switch while avoiding significant excess tOPV stocks after the switch [27]. The challenge for each country was to find this optimal balance. Stock-outs of tOPV before the switch would leave children unimmunized against polio, whereas residual stocks of tOPV could increase the risk for tOPV use after the switch and increase costs associated with the destruction of vaccine doses. Therefore, accurate forecasting, careful procurement planning, close inventory management, and regular monitoring of stock levels were identified as critical actions for countries to minimize wastage of vaccine after the switch.

The switch in its entirety, at the global, regional, and country levels, was an enormous task. Global guidance envisaged the switch activities at the country level to be segregated into 4 phases (Table A1): plan, prepare, implement, and validate [27]. Breaking the stages of the switch into smaller, manageable activities supported the assertion that the switch was feasible. This, combined with a clear delineation of roles and responsibilities for each of the conceived activities at the country, region, and global levels, provided further reassurance of the feasibility of meeting the desired milestones of the switch. The guidance detailed a set of discrete activities and timelines within each of the 4 phases that were likely to be applicable to most of the countries, including 2 key initial milestones to be completed by September 2015: a national tOPV inventory and a budgeted national switch plan. Countries were advised to adapt the guidance to meet their specific needs and, in consultation with stakeholders and partners, develop written national switch plans outlining specific activities that would need to be completed to ensure a successful switch within the country (Table 1). Furthermore, countries and decision-makers were encouraged to conduct a series of activities to facilitate the preparation and implementation of the switch (Table 2).

ACCELERATED GLOBAL HEALTH INITIATIVES NEED CLEAR MESSAGING AND ADEQUATE LEAD TIMES

Providing sufficient advance notice of expectations and timelines to countries, partners, and manufacturers was one of the key factors for the successful switch. At the outset, the GPEI decision on the timing of the switch (Figure 1) was challenging to communicate, difficult to understand, and perceived as infeasible for meeting logistical requirements of implementing the switch. The April 2016 switch date was contingent on a series of epidemiologic and operational readiness criteria. These criteria included the introduction of at least 1 dose of IPV in all countries, the licensure of bOPV for use in routine immunization in all countries, the enhancement of environmental (sewage) surveillance for polioviruses, the creation of a monovalent OPV2 (mOPV2) stockpile for use in any postswitch VDPV2 infection outbreaks, the containment of remaining type 2 polioviruses, and the verification of the eradication of wild type 2 polioviruses [30]. Moreover, all countries had to be free of persistent cVDPV2s, which were cVDPV2s of the same genetic lineages that had been in circulation for ≥6 months [31, 32]. The detection of persistent cVDPV2s was thought to represent a polio eradication program failure since such cVDPV2s had been identified but not eliminated. Such persistent cVDPV2s would also indicate that localized immunity to poliovirus type 2 would be insufficient to justify risking OPV2 withdrawal, which would further reduce immunity and risk the spread of an outbreak. As such, the final so-called go-versus-postpone decision for announcing the switch could not be made until October 2015, well after country planning needed to be initiated. No detection of persistent cVDPV2s during the 6 months before September 2015 would trigger the switch in April 2016, providing countries with 6 months of planning time, whereas any detection during that period would delay the switch until at least April 2017. The ramifications of detecting persistent cVDPV2s between October 2015 and April 2016 were unclear.

To balance the need for epidemiologic conditions conducive to a synchronized global switch and the preparatory time needed by countries and manufacturers, GPEI initially assumed that 6 months of preparation would be sufficient after the global readiness criteria were met. However, after further consultations with countries, partners, and stakeholders, GPEI recognized that at least 1 year of advance planning...
of the switch was necessary. Activities such as vaccine procurement, inventories, securing of budget, bOPV licensing, advocacy, training, and establishing validation processes warranted significant advanced consideration and adequate lead time.

Therefore, in April 2015, SAGE concluded that progress toward elimination of persistent cVDPVs was on track and that countries should plan firmly for April 2016 as the designated date for withdrawal of OPV2, providing 12 months of planning time for the synchronized switch [33]. During the 68th WHA, in May 2015, all countries endorsed the proposed timelines and agreed to conduct the global switch in April 2016 [18]. Later, during its meeting in October 2015, SAGE indicated that it would only consider delaying OPV2 withdrawal if the assessed risk of continued cVDPV2 transmission was high [19]. These messages from SAGE were crucial for persuading countries to commit to planning for the switch. In October 2015, after reviewing the progress toward elimination of cVDPVs and the readiness criteria, SAGE confirmed that every country should stop using tOPV on a single day of its choice between 17 April and 1 May 2016 and remove all stocks of tOPV from service delivery points within 2 weeks of that day.

**LAUNCHING THE SWITCH PLANNING—EARLY OBSTACLES**

The Immunization Systems Management Group (IMG) was the component of the GPEI tasked with overseeing the introduction of IPV, the switch from tOPV to bOPV, and GPEI’s efforts to strengthen routine immunization. The workload and focus of the IMG shifted during 2013–2016, from IPV introduction to the switch, as the world progressed toward meeting the readiness criteria for the switch. Given the enormity of the task and the accelerated time scale, the IMG focused its efforts during the initial 12–18 months on IPV introduction to the switch, as the world progressed toward fulfilling the readiness criteria for the switch. In October 2015, SAGE concluded that progress toward elimination of persistent cVDPV2s was on track and that countries should plan firmly for April 2016 as the designated date for withdrawal of OPV2, providing 12 months of planning time for the synchronized switch [33]. During the 68th WHA, in May 2015, all countries endorsed the proposed timelines and agreed to conduct the global switch in April 2016 [18]. Later, during its meeting in October 2015, SAGE indicated that it would only consider delaying OPV2 withdrawal if the assessed risk of continued cVDPV2 transmission was high [19]. These messages from SAGE were crucial for persuading countries to commit to planning for the switch. In October 2015, after reviewing the progress toward elimination of cVDPVs and the readiness criteria, SAGE confirmed that every country should stop using tOPV on a single day of its choice between 17 April and 1 May 2016 and remove all stocks of tOPV from service delivery points within 2 weeks of that day.

Therefore, in April 2015, SAGE concluded that progress toward elimination of persistent cVDPVs was on track and that countries should plan firmly for April 2016 as the designated date for withdrawal of OPV2, providing 12 months of planning time for the synchronized switch [33]. During the 68th WHA, in May 2015, all countries endorsed the proposed timelines and agreed to conduct the global switch in April 2016 [18]. Later, during its meeting in October 2015, SAGE indicated that it would only consider delaying OPV2 withdrawal if the assessed risk of continued cVDPV2 transmission was high [19]. These messages from SAGE were crucial for persuading countries to commit to planning for the switch. In October 2015, after reviewing the progress toward elimination of cVDPVs and the readiness criteria, SAGE confirmed that every country should stop using tOPV on a single day of its choice between 17 April and 1 May 2016 and remove all stocks of tOPV from service delivery points within 2 weeks of that day.

**LAUNCHING THE SWITCH PLANNING—EARLY OBSTACLES**

The Immunization Systems Management Group (IMG) was the component of the GPEI tasked with overseeing the introduction of IPV, the switch from tOPV to bOPV, and GPEI’s efforts to strengthen routine immunization. The workload and focus of the IMG shifted during 2013–2016, from IPV introduction to the switch, as the world progressed toward meeting the readiness criteria for the switch. Given the enormity of the task and the accelerated time scale, the IMG focused its efforts during the initial 12–18 months on IPV introduction and strengthening routine immunization services (Figure 2) [34]. Discussions on how to operationalize the global synchronized switch effectively did not begin until mid-2014, followed by the establishment of an official Switch Implementation Working Group (SWG).

Some of the early challenges with developing a work plan, defining roles, and agreeing on the basics of the global strategy were related to the inherent complexities of the task (ie, evolving/variable timelines that were dependent on epidemiologic considerations and the fact that the switch was uncharted territory). Nevertheless, following the first SWG meeting, which occurred in Geneva during February 2015, the working group gained momentum, and the plans for progressing became more clear and consolidated. Moreover, as GPEI progressed toward fulfilling the readiness criteria for the switch, the need to initiate switch planning and better define activities became more pressing [35]. Having a more concrete set of activities and timelines helped during the initial discussions with immunization staff at global, regional, and country levels, many of whom had indicated a general lack of confidence with regard to the idealistic expectations of successful synchronization of the global switch. The synchronized switch was perceived to be a new global health endeavor consisting
of unfamiliar activities, with vague definition around the specific tasks (many of which are country specific) that needed completion. These unknowns fostered initial hesitation particularly with respect to the global synchronization component and may have contributed to the inertia in initiating switch-related work globally.

While the switch was ultimately fully accomplished, many of the initial challenges could have potentially jeopardized successful implementation of the switch and, hence, increased the risk for cVDPV2 outbreaks. Specifically, the slow start in initiating the SWG led to inefficiencies and confused messaging that could have been avoided had the necessary human resources been committed at the global level earlier. Nevertheless, the SWG played a critical role in defining milestones, establishing a clear policy and overarching operational objectives and setting firm timelines necessary to achieve the switch.

COMPLEX TASKS NEED SIMPLE SOLUTIONS

In all, a globally synchronized switch with 12 months of planning seemed an insurmountable task for some partners. However, in identifying the smaller individual components and tasks of the switch, the SWG recognized that the switch was no different from other immunization activities, including planning, inventory and stock management, regulatory approval, establishment of technical advisory and management groups, training, communications and advocacy, monitoring and validation, and waste management [27]. Also, the SWG translated the overall vision for the switch into specifically achievable operational components, delineating the core activities and specifying timelines for achieving each objective. This parceling of the switch into smaller, defined tasks provided the necessary initial motivation for launching detailed country-specific plans and activities. Moreover, recognition that the switch actually was a set of activities familiar to immunization staff was instrumental in boosting confidence among GPEI partners and OPV-using countries and territories in the feasibility of achieving the switch objectives.

DEVELOPING A GLOBAL SWITCH WORK PLAN FACILITATED PROGRESS

Working from the adage that countries are more alike than different, the SWG focused on developing guidance for core activities that would be relevant and necessary to meet the ultimate goal and that countries could adapt as needed. The SWG developed a comprehensive work plan with priority activities that warranted action at global, regional, and country levels. Partner agreement on these core activities, including assigning roles and responsibilities, was crucial for clarifying global roles and for advancing regional- and country-level planning with regard to the switch. The SWG realized that the work plan needed to be simple and standardized to the greatest extent possible, identifying core activities within each of the key components of the switch, including decision making, management structure, stock management, training, communications, monitoring, disposal, and validation. Keeping the documents simple and standardized allowed regions and countries to advance the development of their own switch plans that were tailored to meet country-specific needs. This template motivated global, regional,
and country partners to identify key activities specific to them, enabling each partner to conceive their individual roles and responsibilities.

As the switch neared, detailed guidance on logistic protocols, budget templates, monitoring and validation frameworks, and health worker training modules were drafted and disseminated for regional and country adaptation and use, if needed [27]. In this process, some of the initial messages evolved or gained more clarity and depth. Standardizing guidance on switch activities that were likely to be similar across countries provided countries with starting templates for launching their own switch planning process. Standardizing guidance also facilitated a rapid and clear understanding of the key activities that global, regional, and country partners had to undertake to accomplish a globally synchronized switch within 12 months. Although not all aspects of the standardized guidance and tools were applicable to all countries, most of the materials were adapted by regions and further by countries themselves to facilitate local workshops and dissemination.

**AVOID PARALYSIS BY ANALYSIS**

An important milestone for the SWG was the recognition that certain activities and deliberations could occur in parallel to ongoing communication with countries and global partners. For example, guidance on country monitoring and validation of the switch outcomes was a complicated and debated topic in the SWG because of the inherent complexities of developing normative guidance for validating the switch in the 155 countries and territories that used OPV in 2015 [36]. As such, the SWG sought guidance from the SAGE working group on polio. In parallel to this process, the SWG continued moving forward with regional and country workshops to ensure country preparedness for the switch. However, messaging on core components of switch planning activities such as monitoring and validation was incomplete during the initial regional workshops. Even though countries would have preferred standardized guidance on all the components of the switch, waiting for this level of detail to be available before providing any detailed guidance to countries on the switch would have risked serious delays in promoting country planning. Finding the fine balance between consistent, complete messaging and stalled progress was one of the crucial successes of the switch.

**ADAPTABILITY**

A consistent principle among members of the SWG and countries was that of adaptability. The switch was an evolving activity that was defined gradually as the various activities were accomplished by partners and countries worldwide. For example, practical guidance on appropriate disposal of tOPV emerged as a pressing country need. This was a complex topic on which preexisting normative guidance and subject matter expertise was lacking [37]. Comprehensive and practical guidance on the management of tOPV waste went through several iterations as SWG members learned more about the characteristics and implications of different disposal options, consulted with experts on pharmaceutical waste management, and received country-specific feedback. Waste management guidance was ultimately developed and shared with countries; however, some countries already had developed plans in the interim that were difficult to alter. Thus, lessons learned by the SWG were to comprehensively consider all important areas of work early in the process of planning, develop a timeline for rapidly developing and finalizing draft guidance, adapt guidance as new information becomes available and new needs become apparent, and accept that countries may develop customized solutions to common problems. Ongoing modifications of guidance may need to occur in parallel to disseminating draft guidance, and effectively highlighting areas of evolving guidance and their timelines may avoid confusion and foster a sense of flexibility. The adaptability among partners and countries throughout this evolution and tailoring was an important asset to switch success.

**FIELD-TESTING MATERIALS: SWITCH DRY RUNS**

Another enabling factor of the switch’s success was the field-testing of switch activities, guidance, and tools in a diverse range of settings worldwide, which provided some key early lessons (Table 3). These week-long exercises were conducted after the first round of global switch guidance was developed, beginning with a dry run in 2 large states of northern India and continuing with similar exercises in Tanzania, Mongolia, and Cameroon. These dry runs used agendas and materials that were initially developed and tested in a workshop and webinars for global consultants. Dry runs were essentially country-level switch planning workshops that involved a diverse set of participants, such as national decision makers, government and private health workers, cold-chain staff, polio workers, communications staff, regulatory agencies, nongovernmental organizations, civil-society organizations, and multilateral agencies [38]. This broad representation reinforced the contention that the success of the switch was contingent on meeting responsibilities that were shared across multisectoral partners. The dry runs involved meetings with multilevel participants (from the national level to the district level), along with field visits to local facilities to provide contextual information and perspective from key field personnel. The most important message to emerge from the dry-runs was that the switch was perceived as feasible. A clear understanding of the rationale for the switch’s timelines and synchronization motivated staff to develop frameworks for the national operational plans, and many participants enthusiastically provided specific ideas to meet switch objectives.
Table 3. Key Lessons From the Field Exercises, or Dry-Runs, to Simulate the Switch From Trivalent Oral Polio Vaccine (OPV) to Bivalent OPV

| Switch Component | Strengths |
|------------------|-----------|
| Overall          | Strong partnership, excellent coordination, adaptability, practicality, and commitment to success |
| Policy and timeline | Strong and comprehensive communication of rationale encouraged buy-in, many contingency plans, objective and risk based, and guided by respected advisory group (SAGE and SAGE Working Group) |
| Switch Implementation Working Group | Trust and collaboration; coordination; core team of broad skill sets, right size, and good previous working relationships; and shared mission, responsibility, and absence of personal agenda |
| Developing guidance and tools | Comprehensive approach, lead agency with multiagency input, consistency in messaging, rapid turnaround, and multilingual translations |
| Field testing materials | Broad platforms (webinars, dry-runs, and workshops), innovative approaches, adaptability, and disseminating and testing simultaneously |
| Consultant and country workshops | Real-world input, enabling ambassadors and advocates, surge capacity of support, passive diffusion of messages, and global followed by regional workshops |

Table 4. Summary of Key Challenges and Lessons Learned From the Global Planning of the Switch From Trivalent Oral Polio Vaccine (OPV) to Bivalent OPV

| Switch Component | Strengths | Weaknesses | Lessons Learned |
|------------------|-----------|-----------|----------------|
| Overall          | Delays in establishing a switch working group, inadequate resources, no clear work plan and competing priorities among partners at the outset, and pessimism about meeting switch timelines | Early senior leadership and guidance, establish clear vision and objectives, establish clear roles and responsibilities, and foster optimism |
| Policy and timeline | Complex messaging (eg, go-versus-postpone decision), unclear timelines for OPV2 withdrawal, inconsistent and late guidance on disposal, and lack of operational considerations | Early incorporation of operational feasibility into policies and timelines, and clear and consistent messaging facilitates optimism and motivates partners |
| Switch Implementation Working Group | Delays in establishing work plan, roles, and responsibilities; and lengthy process of reaching consensus challenging for accelerated switch timelines | Early, multiday, face-to-face meeting crucial for advancing work; important to achieve early agreement on the basics of strategy, structure, and roles; and strategic work plan (complex objectives can be achieved if broken into smaller manageable tasks) |
| Developing guidance and tools | Unclear process of finalizing and disseminating, inadequate use of professional copyediting and communication services, excess documents and tools, and complex guidance early in the switch planning | Simple and standardized allows scalability; strategic dissemination fosters motivation and optimism (simple first, then more complex), provide guiding principles and countries will adapt to meet needs, and plan for copyediting and translating |
| Field testing materials | Potential for confusion with changing messages and materials, resource intensive, and excess documents | Innovative approach to rapid field-testing of materials; provides platform for global staff to interact with field; once rationale clearly explained, logistics became clearer to participants; advance planning is important but adaptability is crucial; and avoiding document overloads to participants for first country sensitization and planning missions (excess documents can cause confusion) |
| Consultant and country workshops | Inefficient if consultants not used, inadequate pool of skilled consultants, inability to promise assignments, and language restrictions | Advance planning; invest in roster of consultants; hybrid workshops of consultants, regional, and country office staff useful; and replicate/adapt agenda and materials once tested globally |

Abbreviations: OPV2, poliovirus type 2 component of oral polio vaccine; SAGE, Strategic Advisory Group of Experts on Immunization.
SWITCH AMBASSADORS—CONSULTANT AND COUNTRY WORKSHOPS

In May 2015, the SWG coordinated a global switch training workshop for consultants and regional office focal points from all of the WHO and UNICEF regions. This workshop was instrumental for vetting the initial global switch guidance and was a unique opportunity to raise switch awareness on detailed activities necessary for implementation, to seek input on materials developed to date, and to provide a platform for voicing country and region needs. The workshop attendees became switch ambassadors and later provided invaluable guidance to countries through direct support in country planning and implementation or through other activities (eg, leading and facilitating regional country workshops and dry runs). The materials vetted and revised at this workshop, including the agenda, were modified and replicated throughout the world in numerous regional workshops, webinars, and dry runs and provided the foundation for developing country switch plans. These workshops, webinars, and dry runs were the backbone of the global planning and implementation of the synchronized switch.

NATIONAL AND REGIONAL OWNERSHIP—A CRITICAL FACTOR FOR SWITCH SUCCESS

Early engagement with the regional offices by the SWG was critical to the success of the switch. Developing a core set of guidance and tools reflecting the switch strategy before engaging the regions and countries provided a useful frame of reference and a platform for concrete discussions. Engagement with regional offices provided the necessary input for customization of the guidance and identified approaches to field-testing the materials rapidly during the dry run. Initial consultations through global workshops and calls included all regional offices simultaneously, which provided transfer and exchange of useful ideas across and within the regions. For example, the South-East Asia Regional Office developed a tracking tool for monitoring country-specific switch progress, and the Regional Office for the Americas developed monitoring and validation tools that were then adapted for other regions of the world. Later, each of the regions adopted globally available materials or developed its own materials that catered to the needs of countries in its region. The SWG maintained close communication and collaboration with the regional offices, and it monitored regional progress through frequent conference calls, emails, and consultations, providing additional guidance and support as needed. Overall, ownership of the switch by the regional offices—by monitoring progress, providing country support, and identifying issues warranting global attention—was critical to the success of the globally synchronized switch.

CONCLUSION

Global health initiatives are known to have an emergent quality, but the switch also had a compressed timeline. The initial approach to global switch planning did not meet the requirements of the task. As switch planning progressed and the switch window approached, the strengths of the IMG percolated throughout the partnership to help address the early shortcomings of the switch planning (Table 4). Overall, the globally synchronized switch was a success, with all countries reporting the cessation of tOPV use close to SAGE’s recommended timelines. The success of the synchronized switch globally was because of flexibility, clear communication, coordination and collaboration, and strong leadership across all levels, including the GPEI partnership. Dissemination of clear, simple messages gave shape to switch activities, provided optimism and confidence, and allowed accelerated progress globally. Communications were modified as needed to attain more depth and to meet the evolving needs of the regions and countries. Activities among the partners, regions, and countries were effectively coordinated to avoid duplication of efforts, to foster exchange of ideas, and to advocate for necessary resources. A true collaboration developed among

![Table A1. Proposed Switch Calendar for Switch Activities Disseminated to Countries in April 2015](https://academic.oup.com/jid/article-abstract/216/suppl_1/S183/3935056/Downloaded_from_https://academic.oup.com/jid/article-abstract/216/suppl_1/S183/3935056)
all global, regional, and country partners that was built on trust, technical strength, and optimism—an infectious can-do spirit—and resulted in successful withdrawal of OPV2 in a synchronized manner from the cold chain worldwide. The global switch from tOPV to bOPV has set an important precedent regarding the kind of synchronized, cooperative international efforts that are possible and upon which future efforts can be built.

Notes

Disclaimer. The findings, interpretations, and conclusions expressed in this article are those of the authors and do not necessarily reflect the policies or views of UNICEF, the WHO, the Bill and Melinda Gates Foundation, or the Centers for Disease Control and Prevention.

Financial support. This work was supported by the Bill and Melinda Gates Foundation (grant OPP1095024 to M. M. P., J. G., C. L. V., and S. W. and contracts to F. K. and H. E.).

Supplement sponsorship. This work is part of a supplement coordinated by the Task Force for Global Health with funding provided by The Bill and Melinda Gates Foundation and the Centers for Disease Control and Prevention.

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland. http://www.polioeradication.org/Dataandmonitoring/Poliolisthissweek.aspx. Accessed 15 February 2017.
2. Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland. http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx. Accessed 15 February 2017.
3. Global Polio Eradication Initiative. Polio Eradication and Endgame Strategic Plan 2013–2018. WHO/POLIO/I30.2. http://www.polioeradication.org/Portals/0/Document/Resources/Strategy/Work/PEESP_EN_US.pdf. Accessed 23 August 2016.
4. Patel M, Orenstein W. A world free of polio—the final steps. N Engl J Med 2016; 374:501–3.
5. Duintjer Tebbens RJ, Pallansch MA, Kim JH et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013; 33:680–702.
6. Garon J, Seib K, Orenstein WA et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines 2016; 15:1–16.
7. Patel M, Zipursky S, Orenstein W, Garon J, Zaffran M, Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines 2015; 14:749–62.
8. Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006; 26:1471–505.
9. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis 2014; 210:S475–84.
10. Thompson KM, Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines 2012; 11:449–59.
11. World Health Organization. Strategic Advisory Group of Experts on immunization (SAGE). Geneva: WHO. 20–22 October 2015. http://www.who.int/immunization/sage/meetings/2015/october/sage_report_oct_2015.pdf?ua=1. Accessed 26 October 2015.
12. World Health Organization. Meeting of the SAGE Polio Working Group. Geneva: WHO. 7–8 September 2015. http://www.who.int/immunization/sage/meetings/2015/october/sage_report_draft_Final_clean.pdf?ua=1. Accessed 10 October 2015.
13. Meeting of the Strategic Advisory Group of Experts on immunization, April 2012—conclusions and recommendations. Wkly Epidemiol Rec 2012; 87:201–16.
14. Meeting of the Strategic Advisory Group of Experts on immunization, November 2012—conclusions and recommendations. Wkly Epidemiol Rec 2013; 88:1–16.
15. Meeting of the Strategic Advisory Group of Experts on immunization, April 2013—conclusions and recommendations. Wkly Epidemiol Rec 2013; 88:201–6.
16. Meeting of the Strategic Advisory Group of Experts on immunization, November 2013—conclusions and recommendations. Wkly Epidemiol Rec 2014; 89:1–20.
17. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014—conclusions and recommendations. Wkly Epidemiol Rec 2014; 89:221–36.
18. World Health Organization. Sixty-eighth World Health Assembly; Polio eradication report by the secretariat. http://apps.who.int/ghr/ebwha/pdf_files/WHA68/A68_21-en.pdf. Accessed 24 August 2016.
19. Meeting of the Strategic Advisory Group of Experts on immunization, October 2015—conclusions and recommendations. Wkly Epidemiol Rec 2015; 90:681–99.
20. Gupta SK, Sosler S, Lahariya C. Introduction of haemophilus influenzae type b (Hib) as pentavalent (DPT-HepB-Hib) vaccine in two states of India. Indian Pediatr 2012; 49:707–9.
21. Sadoh AE, Nwaneri DU, Ogbogboho BC, Sadoh WE. Effect of introduction of pentavalent vaccine as replacement for diphtheria-tetanus-pertussis and hepatitis b vaccines on vaccination uptake in a health facility in nigeria. Vaccine 2016; 34:2722–8.
22. Centers for Disease C, Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—advisory committee on immunization practices (ACIP). 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258–61.
23. Carole Tevi-Benissan M, Moturi E, Anya BM, et al. Contribution of polio eradication initiative to effective new vaccine introduction in africa, 2010–2015. Vaccine 2016; 34:5193–1998.
24. Lam E, McCarthy A, Brennan M. Vaccine-preventable diseases in humanitarian emergencies among refugee and internally-displaced populations. Hum Vaccin Immunother 2015; 11:2627–36.
25. Global polio eradication initiative: 10th meeting of the independent monitoring board. Wkly Epidemiol Rec 2014; 89:361–7.
26. Ferguson NM, Cucunubå ZM, Dorigatti I, et al. Countering the Zika epidemic in Latin America. Science 2016; 353:353–4.
27. World Health Organization. Guidance for implementing the switch. http://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/implementation/en/. Accessed 24 August 2016.
28. World Health Organization: Global switch in oral polio vaccines—situation report. http://maps.who.int/OPV_switch/. Accessed 24 August 2016.
29. Hampton LM, Farrell M, Ramirez-Gonzalez A et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine—worldwide, 2016. MMWR Morb Mortal Wkly Rep 2016; 65:934–8.
30. World Health Organization. Type 2 OPV withdrawal: Update on readiness and preparations for the switch for April 2015 SAGE session. http://www.who.int/immunization/sage/meetings/2015/april/4_Switch_Update_Background_Paper_April_SAGE_2015_22mar15HJREV.pdf. Accessed 11 September 2016.
31. World Health Organization. 9th Meeting of the SAGE Polio Working Group. Geneva: WHO. 30–31 July 2014. http://www.who.int/immunization/sage/meetings/2014/october/1_SAGE_Note_for_the_Recordv14July2014.pdf?ua=1. Accessed 25 August 2016.
32. World Health Organization. OPV cessation. Protocol for a global coordinated switch from trivalent OPV to bivalent OPV. Draft version 9 October 2014. http://www.who.int/immunization/sage/meetings/2014/october/2_Switch_Protocol_SAGE_Version_9_Oct14.pdf?ua=1. Accessed 25 August 2016.
33. Meeting of the Strategic Advisory Group of Experts on immunization, April 2015: conclusions and recommendations. Wkly Epidemiol Rec 2015; 90:261–78.
34. Introduction to inactivated polio vaccine and switch from trivalent to bivalent oral poliovirus vaccine worldwide, 2013–2016. Wkly Epidemiol Rec 2015; 90:337–43.
35. Meeting of the strategic advisory group of experts on immunization, October 2014—conclusions and recommendations. Wkly Epidemiol Rec 2014; 89:561–76.
36. Farrell M, et al. Monitoring and Validation of the Global Replacement of tOPV with bOPV, April–May 2016. J Infect Dis 2017; 216 (suppl 1):S193–201.
37. Wansoek S, Ramirez-Gonzalez A, Dolan S, et al. Disposing of excess vaccines after the withdrawal of oral polio vaccine. J Infect Dis 2017; 216 (suppl 1):S202–8.
38. Global Immunization News; July 2015—Workshop on planning for the switch in oral polio vaccines in Mongolia. http://www.who.int/entity/immunization/GIN_July_2015.pdf?ua=1. Accessed 24 August 2016.